科拓生物(300858) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 reached ¥77,612,862.67, representing a 31.49% increase compared to ¥59,025,584.73 in the same period last year[5] - Net profit attributable to shareholders was ¥20,329,624.63, up 9.79% from ¥18,516,444.83 year-on-year[5] - Basic earnings per share increased by 14.29% to ¥0.08 from ¥0.07 in the same period last year[5] - Total operating revenue for the current period reached ¥77,612,862.67, a significant increase of 31.5% compared to ¥59,025,584.73 in the previous period[27] - Net profit for the current period was ¥20,329,624.63, representing an increase of 9.8% from ¥18,516,444.83 in the previous period[28] Cash Flow - The net cash flow from operating activities was negative at -¥529,716.47, a decline of 101.84% compared to ¥28,714,195.39 in the previous year[14] - The company's cash flow from operating activities showed improvement, with a notable increase in cash inflows compared to the previous period[29] - Operating cash inflow totaled $66,962,274.75, down 24.0% from $88,076,558.40 in the previous period[30] - Operating cash outflow increased to $67,491,991.22, up 13.5% from $59,362,363.01 in the previous period[30] - Net cash flow from operating activities was negative at -$529,716.47, compared to a positive $28,714,195.39 in the previous period[30] - Cash inflow from investment activities was $456,343,362.38, a decrease of 25.3% from $611,003,135.92 in the previous period[31] - Net cash flow from investment activities increased to $102,761,836.24, up 71.5% from $59,957,195.27 in the previous period[31] - Cash outflow for purchasing fixed assets and intangible assets was $95,438,950.78, up 76.6% from $54,078,280.88 in the previous period[31] - Cash outflow from financing activities was $416,094.00, a significant decrease from $3,470,324.71 in the previous period[31] - The net increase in cash and cash equivalents was $101,816,024.92, compared to $85,201,065.95 in the previous period[32] - The ending balance of cash and cash equivalents was $207,401,392.39, down from $273,737,504.09 in the previous period[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,932,060,722.81, a 0.86% increase from ¥1,915,597,694.39 at the end of the previous year[5] - Non-current assets totaled ¥858,551,717.68, down from ¥960,892,687.72 in the previous period, indicating a decrease of 10.6%[25] - Current liabilities decreased slightly to ¥94,114,470.60 from ¥96,188,516.35, a reduction of 2.2%[25] - The total current assets increased to ¥1,073,509,005.13 from ¥954,705,006.67, representing a growth of approximately 12.4%[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,685[16] - The largest shareholder, Sun Tiansong, holds 19.94% of shares, totaling 52,538,822 shares[16] - The top ten shareholders hold a combined total of 70.93% of the shares, indicating a concentrated ownership structure[16] - The company has no preferred shareholders or changes in restricted shares during the reporting period[18] Investments and Future Plans - The company reported a significant increase in investment income, which rose by 250.54% to ¥982,169.09 from ¥280,184.64 year-on-year[11] - The company plans to continue expanding its business in the probiotics and micro-ecological preparations sectors, which have shown significant growth[11] - The company plans to adjust the investment scale and structure of the food sector R&D production base project, reallocating surplus funds of ¥62.58 million to supplement working capital[21] - The project is expected to reach a usable state by December 31, 2026[21] - The company plans to expand its market presence and invest in new technologies to drive future growth[29] Research and Development - Research and development expenses were reported at ¥7,884,151.19, slightly down from ¥8,008,843.89 in the previous period[27] Audit Information - The first quarter report was not audited[32]